1) The anamorph (imperfect) form of the organism is called Scedosporium apiospermum
(formerly Monosporium apiospermum), and was shown by Emmons (36) in 1944 to be the same organism as P boydii.
P boydii and its asexual form, Scedosporium apiospermum
are ubiquitous saprophytes in polluted streams and decaying vegetation.
Vfend was initially approved in the US for the primary treatment of acute invasive aspergillosis and salvage therapy for rare but serious infections caused by the pathogens Scedosporium apiospermum
and Flusarium spp.
Pseudallescheria boydii, previously categorized in the genera Allescheria, Monosporium, and Petriellidium, is the perfect (sexual) form of Scedosporium apiospermum
Serious fungal infections caused by Scedosporium apiospermum
and Fusarium spp, including F.
Posaconazole has shown promise in the treatment of invasive fusariosis, Scedosporium apiospermum
infections, disseminated phaeohyphomycosis due to Exophiala spinifera, and refractory coccidioidomycosis infections (36-40).
fungal infections caused by pathogens Scedosporium apiospermum
VFEND is currently approved in the United States for the treatment of invasive aspergillosis, esophageal candidiasis and as salvage therapy for fungal infections caused by pathogens Scedosporium apiospermum
and Fusarium species.
Such pathogens include Scedosporium apiospermum
(teleomorph Pseudallescheria boydii) and S.
Voriconazole was approved by the Food and Drug Administration in May 2002 for the treatment of invasive aspergillosis and refractory infections of Scedosporium apiospermum
and Fusarium spp.
soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy.
Paravertebral collection showed spondylodiscitis (T8-T9), caused by Scedosporium apiospermum